BIOMAT Database Logo BIOMAT Database Logo

Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. 1991

H Samonigg, and H Stöger, and A K Kasparek, and M Schmid, and J Dusleag, and K Pfeiffer, and M Smola, and P Steindorfer, and P Lechner
Department of Internal Medicine, Karl Franzens-University, Graz, Austria.

A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF). Treatment was repeated every 3 weeks. In all 53 patients were evaluable for response. A total of 12 subjects had failed prior chemotherapy for metastatic disease. In response to PMF treatment we observed 21 partial remissions and 3 complete remissions, amounting to a total response rate of 45%. The median duration of response was 39 weeks, and median survival was 56 weeks. Dose-limiting side effects were leukopenia (40 cases) and thrombocytopenia (11 patients). Nausea and vomiting was experienced by 93% of subjects; in 56% of cases it reached WHO stage II-III. Alopecia occurred in 18% of our patients. Our results suggest that PMF represents an active regimen in the treatment of advanced breast cancer and yields a response rate of 45%. Considering that the majority of our patients had not received prior chemotherapy, the question remains open as to whether a 45% response rate outweighs the observed toxicity.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008942 Mitoxantrone An anthracenedione-derived antineoplastic agent. Mitozantrone,CL-232325,DHAQ,Mitoxantrone Acetate,Mitoxantrone Hydrochloride,Mitroxone,NSC-279836,NSC-287836,NSC-299195,NSC-301739,NSC-301739D,Novantron,Novantrone,Onkotrone,Pralifan,Ralenova,Acetate, Mitoxantrone,CL 232325,CL232325,Hydrochloride, Mitoxantrone,NSC 279836,NSC 287836,NSC 299195,NSC 301739,NSC 301739D,NSC279836,NSC287836,NSC299195,NSC301739,NSC301739D
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D011238 Prednimustine Ester of CHLORAMBUCIL and PREDNISOLONE used as a combination alkylating agent and synthetic steroid to treat various leukemias and other neoplasms. It causes gastrointestinal and bone marrow toxicity. Leo-1031,NSC-134087,Sterecyt,Stereocyt,Stéréocyt,Leo 1031,Leo1031,NSC 134087,NSC134087
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

H Samonigg, and H Stöger, and A K Kasparek, and M Schmid, and J Dusleag, and K Pfeiffer, and M Smola, and P Steindorfer, and P Lechner
First-line mitoxantrone chemotherapy for advanced breast cancer.
August 1986, Cancer treatment reports,
H Samonigg, and H Stöger, and A K Kasparek, and M Schmid, and J Dusleag, and K Pfeiffer, and M Smola, and P Steindorfer, and P Lechner
Mitoxantrone and 5-fluorouracil modulated by the pure (6S) stereoisomer of leucovorin as second-line chemotherapy for advanced breast cancer.
January 1994, European journal of cancer (Oxford, England : 1990),
H Samonigg, and H Stöger, and A K Kasparek, and M Schmid, and J Dusleag, and K Pfeiffer, and M Smola, and P Steindorfer, and P Lechner
Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer.
February 2005, Onkologie,
H Samonigg, and H Stöger, and A K Kasparek, and M Schmid, and J Dusleag, and K Pfeiffer, and M Smola, and P Steindorfer, and P Lechner
Prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer in postmenopausal women. A phase II trial.
January 1988, Acta oncologica (Stockholm, Sweden),
H Samonigg, and H Stöger, and A K Kasparek, and M Schmid, and J Dusleag, and K Pfeiffer, and M Smola, and P Steindorfer, and P Lechner
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer.
January 1985, Investigational new drugs,
H Samonigg, and H Stöger, and A K Kasparek, and M Schmid, and J Dusleag, and K Pfeiffer, and M Smola, and P Steindorfer, and P Lechner
Mitoxantrone and prednimustine combination chemotherapy in breast cancer.
July 1989, Journal of chemotherapy (Florence, Italy),
H Samonigg, and H Stöger, and A K Kasparek, and M Schmid, and J Dusleag, and K Pfeiffer, and M Smola, and P Steindorfer, and P Lechner
Mitoxantrone, methotrexate, and 5-fluorouracil combination chemotherapy as first-line treatment in stage IV breast cancer.
January 1986, Cancer,
H Samonigg, and H Stöger, and A K Kasparek, and M Schmid, and J Dusleag, and K Pfeiffer, and M Smola, and P Steindorfer, and P Lechner
First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine.
January 1989, Oncology,
H Samonigg, and H Stöger, and A K Kasparek, and M Schmid, and J Dusleag, and K Pfeiffer, and M Smola, and P Steindorfer, and P Lechner
Mitoxantrone, folinic acid, 5-fluorouracil and prednisone as first-line chemotherapy for advanced breast carcinoma. A phase II study.
January 1993, European journal of cancer (Oxford, England : 1990),
H Samonigg, and H Stöger, and A K Kasparek, and M Schmid, and J Dusleag, and K Pfeiffer, and M Smola, and P Steindorfer, and P Lechner
Mitoxantrone, L-leucovorin and 5-fluorouracil: an effective and well tolerated first-line treatment for advanced breast cancer.
January 1999, Tumori,
Copied contents to your clipboard!